Biomerica, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended May 31, 2016, with fiscal 2015 comparatives. Although the request metadata refers to “2015 Q4,” this filing reports a full fiscal year, not a quarterly period. The company develops and sells medical diagnostic kits through clinical laboratories and point-of-care channels.
Financial results and liquidity
| Metric | FY2016 | FY2015 |
|---|---|---|
| Net sales | $5.140 million | $4.962 million |
| Gross profit / margin | $1.524 million / 29.7% | $1.542 million / 31.1% |
| Operating expenses | $2.351 million | $2.212 million |
| Operating loss | $826,952 | $670,595 |
| Net loss | $1.500 million | $331,410 |
| Basic and diluted loss per share | $0.20 | $0.04 |
| Cash used in operating activities | $208,782 | $405,481 |
| Cash and cash equivalents at year-end | $1.889 million | $1.088 million |
| Working capital | $4.329 million | $3.868 million |
Sales increased 3.6%. Cost of sales rose faster than revenue, increasing to 70.3% of sales from 68.9%; gross margin therefore narrowed. SG&A increased 6.2% to $1.571 million, while R&D increased to $780,333 from $733,640. The balance sheet reported $506,027 of current liabilities and no debt balance is identified in the provided filing text. Total shareholders’ equity was $5.220 million.
Operating cash use improved year over year, while investing activities used $95,192. Financing provided $1.106 million, including $995,978 net proceeds from a private stock placement and $109,936 from option exercises. The company reported no off-balance-sheet arrangements.
Material changes and unusual items
- Net loss widened substantially, principally due to a $1.038 million valuation allowance against deferred tax assets. The income statement reports income tax expense of $703,800 in FY2016 versus a tax benefit of $315,024 in FY2015. Management described the valuation allowance as a non-cash charge; deferred tax assets fell to $41,000 from $744,000.
- Geographic sales shifted: Asia increased to $1.731 million from $1.016 million, while Europe declined to $2.166 million from $2.716 million. U.S. sales declined to $995,000 from $1.042 million. Foreign markets accounted for most revenue.
- One distributor represented 30.3% of FY2016 sales, up from 16.3%. Two customers represented 60.3% of year-end gross accounts receivable.
- Backlog rose to approximately $386,000 from $154,000.
- On May 25, 2016, Celtis Pharm agreed to purchase 333,334 shares at $3.00 per share for approximately $1.0 million and entered an exclusive South Korean marketing license for InFoods IBS products. Potential license fees are milestone-based, up to $1.25 million; the agreement also includes royalties and stated minimum royalties of $7.25 million, subject to product and regulatory milestones and contract terms.
Outlook, risks, and contingencies
The company provided no quantified revenue or earnings guidance. Management is developing two gastrointestinal tests, including InFoods, a diagnostic-guided approach intended to identify foods associated with IBS symptoms. The clinical-laboratory product is planned as the first submission for U.S. regulatory clearance; the company said it intended to pursue a de novo 510(k) pathway. Clearance, commercialization, and related revenues remain uncertain.
Key risks include dependence on distributors and customer concentration; regulatory clearance and ongoing compliance in the U.S. and foreign markets; competition from substantially larger companies; availability and cost of certain raw materials; product liability and potential recalls; foreign-market, currency, shipping, and manufacturing risks; and the need for future financing. The Celtis agreement may be cancelled if U.S. clearance is not obtained by December 31, 2017, unless extended by mutual agreement. No legal proceedings were pending at May 31, 2016, and the filing states no material contingency was identified as then pending.
Management reported effective disclosure controls and internal control over financial reporting at May 31, 2016; the auditor did not provide an internal-control attestation. The company’s common stock began trading on Nasdaq on August 26, 2016, after the fiscal year-end.
Important facts for investors to verify
- Progress, clinical evidence, regulatory pathway, timing, and costs for InFoods and the other gastrointestinal tests.
- Whether the Celtis milestone payments, Korean approval, and minimum-royalty provisions are achieved and when any revenue may be recognized.
- Sustainability of the distributor responsible for 30.3% of sales and collectability of receivables concentrated among two customers.
- Drivers of the declining gross margin and the company’s ability to fund operations while reporting operating losses and using cash.
- Recoverability of deferred tax assets and any constraints on use of tax-loss and credit carryforwards.
- For clarity, the filing’s MD&A refers to a $703,800 valuation allowance charge, while the tax note describes a $1.038 million valuation allowance increase; the precise reconciliation should be checked against the full statements and notes.